Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...
Surrounded by family and friends, Lane rang the bell, which symbolizes the end of cancer treatments, at Brenner Children’s ...
Results from the phase 3 EPCORE DLBCL-1 clinical trial show that patients with relapsed or refractory diffuse large B-cell ...
Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...
Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback